Hyderabad-based Vivimed Labs has acquired Uquifa,
manufacturer of active pharma ingredients (APIs) and intermediates with
operations in Spain and Mexico, for a consideration of $ 55 million.
"In a move to bring in strategic growth into its product mix and expand the footprint in Europe and the Americas, the company has taken a measured stride with the acquisition of Uquifa Spain and Uquifa Mexico," Vivimed said in a release.
The investment consideration of $ 55 million is paid by equity infusion of $ 20 million, debt financing of $ 25 million and the balance of $ 10 million by way of deferred payment, it added.
Uquifa will become the active pharmaceutical ingredient (API) division of the Vivimed group. The company said the acquisition would strengthen the company's current position in pharma APIs and intermediates while significantly improving the cost competitiveness of Uquifa.
According to the company, the acquisition of Uquifa will add to its multi-geographical locations and knowledge base.
Uquifa sells in over 70 countries and has over 150 active DMFs filed and 20 COS approved. The company has a net assets of $ 65 million and gross assets of $ 100 million as of this June.
"In a move to bring in strategic growth into its product mix and expand the footprint in Europe and the Americas, the company has taken a measured stride with the acquisition of Uquifa Spain and Uquifa Mexico," Vivimed said in a release.
The investment consideration of $ 55 million is paid by equity infusion of $ 20 million, debt financing of $ 25 million and the balance of $ 10 million by way of deferred payment, it added.
Uquifa will become the active pharmaceutical ingredient (API) division of the Vivimed group. The company said the acquisition would strengthen the company's current position in pharma APIs and intermediates while significantly improving the cost competitiveness of Uquifa.
According to the company, the acquisition of Uquifa will add to its multi-geographical locations and knowledge base.
Uquifa sells in over 70 countries and has over 150 active DMFs filed and 20 COS approved. The company has a net assets of $ 65 million and gross assets of $ 100 million as of this June.
Great work ! Thanks for sharing
ReplyDeleteStrides Pharma Global Private Limited
USFDA approvals
pharmaceutical
Sensex